By continuing to browse our website, you agree to the storing of first- and third-party cookies and related technologies on your device to enhance site access and navigation, analyze site usage, authenticate users, facilitate transactions, and assist in our marketing efforts. Please read our privacy notice to learn more.
UNMC_Acronym_Vert_sm_4c
University of Nebraska Medical Center

As Dengue Fever Fears Grow In U.S., First Prevention Pill Has Promising Trial

Forbes A pill to prevent dengue fever—a viral infection also called “breakbone fever” for the severe pain it can cause—could be on the horizon, according to data presented by Johnson & Johnson on Friday, promising news that could signal a future treatment against what experts warn is a pressing and growing health threat that could soon return to plague the United States.

An antiviral pill developed by pharma giant Johnson & Johnson appeared to protect people against dengue when exposed to a virus that causes the disease, according to early data from the company’s clinical trial presented at the American Society of Tropical Medicine & Hygiene Annual Meeting in Chicago.

The trial involved healthy volunteers taking the drug—called JNJ-1802—or an inert placebo for 26 days and being injected on day five with a type of dengue virus, a type of study known as a challenge trial.

twitter facebook bluesky email print

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

iWkijjtQWy YQlpAcMD Ug yfnOh